Advances in borderline resectable pancreatic adenocarcinoma.

Deepak Vadehra, Patrick N Salibi, Derek R McHaffie, Jesse Sulzer, David A Iannitti, Jimmy J Hwang

Clinical advances in hematology & oncology : H&O 2020 May

filter terms:

Pancreatic adenocarcinoma is one of the most lethal cancers in oncology. Pancreatic cancer is the third most common cause of cancer-related mortality in the United States. As the years have progressed, the importance of a multidisciplinary and multimodal approach to pancreatic cancer care has been recognized and is now recommended in all major society guidelines. A subset of pancreatic cancer, borderline resectable pancreatic cancer (BRPC), has emerged as a distinct clinical entity for which specialized treatment plans are now being developed. The medical oncologist, surgical oncologist, and radiation oncologist must work jointly to help deliver the best clinical outcome for the patient with pancreatic cancer. In this discussion, we describe the current state of surgical, locoregional therapies and systemic therapy in BRPC.

Citation

Deepak Vadehra, Patrick N Salibi, Derek R McHaffie, Jesse Sulzer, David A Iannitti, Jimmy J Hwang. Advances in borderline resectable pancreatic adenocarcinoma. Clinical advances in hematology & oncology : H&O. 2020 May;18(5):280-288